BioCentury
ARTICLE | Top Story

Selecta, Sanofi in food allergy deal

November 29, 2012 1:57 AM UTC

Selecta Biosciences Inc. (Watertown, Mass.) granted Sanofi (Euronext:SAN; NYSE:SNY) exclusive, worldwide rights to develop and commercialize a tolergenic, antigen-specific immunotherapy against an undisclosed food allergen using Selecta's Synthetic Vaccine Particle (SVP) platform. Sanofi also has an option to develop two additional SVP immunotherapies against undisclosed food or aeroallergens. Selecta is eligible to receive up to $300 million for each resulting immunotherapy, plus double-digit tiered royalties for each commercialized product. Selecta said the companies are not disclosing additional financial details. ...